Coatomer protein complex subunit beta 2, also known as COPB2, may act as an oncogene in certain types of cancer. Until now, no systematic pan-cancer analysis has been performed on COPB2. This study, published in BioMed Research International, used The Cancer Genome Atlas and the Gene Expression Omnibus datasets to analyze the oncogenic role of COPB2.
It was found that most cancer types overexpressed the COPB2 protein. This overexpression correlated with tumor prognosis in a significant way, particularly for kidney and endometrial cancers. In breast and ovarian tissue, phosphorylated S859 was expressed highly as well. Lastly, the researchers found that COPB2 was also found to correlate with chemotherapy sensitivity, in addition to genetic alteration and immune cell infiltration.
This pan-tumor study is important because it provides insight into the tumorigenic properties of COPB2 and a relatively comprehensive understanding of how COPB2 promotes cancer growth [1].
Source:
[1] Wu, B., Wu, Y., Guo, X., Yue, Y., Li, Y., He, X., Chen, Y., Zhao, W., Liu, J., Wu, X., Shen, A., & Zhang, S. (2021). An integrative pan-cancer analysis of the oncogenic role of COPB2 in human tumors. BioMed Research International, 2021, 1 – 18. https://doi.org/10.1155/2021/7405322
